Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rubius closes Series C round of more than $100mm

Executive Summary

Rubius Therapeutics Inc. (cell therapies) raised $101.2mm in an oversubscribed Series C financing. According to the Form D, 27 investors participated. The company is developing Red-Cell Therapeutics (RCT) allogeneic products with extended stability and storage. Rubius will use the funds to move RTC therapies into the clinic and enhance its manufacturing capabilities.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies